Positive maintenance data for B-MS/Otsuka's Abilify

Maintenance therapy with the US drug major Bristol-Myers Squibb and Otsuka Pharmaceutical's co-developed atypical antipsychotic Abilify (aripiprazole) significantly delayed the time to relapse in adults with bipolar I disorder who had been stabilized and maintained on the agent for at least six weeks, according to findings of a randomized, double-blind, placebo-controlled study of patients with a recent manic or mixed episode, published in the current issue of the Journal of Clinical Psychiatry.